# 1. Financial Performance ## A. Key Figures * **Proforma Revenue (Q3 FY26):** **₹2,366 Cr** (+15% YoY) * **Aster Revenue from Operations (Q3 FY26):** **₹1,186 Cr** (+13% YoY) · **Labs Revenue:** **₹39 Cr** (+17% YoY) * **Kerala Cluster Revenue (Q3 FY26):** **₹629 Cr** (+20% YoY) · **K&M Cluster Revenue:** **₹383 Cr** (+7% YoY) * **Operating EBITDA (Proforma):** **₹503 Cr** (+22% YoY) · **Margin:** **21%** * **Normalised PAT (Post NCI):** **₹98 Cr** (Q3 FY26, +22% YoY) · **₹298 Cr** (9M FY26, +19% YoY) * **Cash & Cash Equivalents:** **₹1,255 Cr** · **Gross Debt:** **₹631 Cr** ## B. Revenue Drivers & Business Mix * **Strong Proforma Growth:** Integrated platform delivered healthy double-digit revenue growth, driven by **8–9% patient volume expansion** and **8–10% inpatient ARPP gains** each quarter. * **Core Momentum:** Mature hospitals (>7 years) achieved **14% revenue growth**, while 3–7 year units delivered **10% top-line and 28% EBITDA growth**, reflecting strong operating leverage. * **Regional Leadership:** Kerala emerged as top performer with **20% revenue growth**, supported by cost efficiencies and high patient demand on a strong base. * **Mixed Performance in K&M:** Revenue growth of **7%** despite **9% inpatient volume decline**, offset by **17% ARPP increase**, though competitive pressures and scheme exits weighed on volumes. ## C. Margin & Profitability Trends * **EBITDA Outpaces Revenue:** Operating EBITDA grew **22% YoY** with **21% margin**, showcasing disciplined cost control and operating leverage across the platform. * **Mature Unit Strength:** Mature units (~60% of revenue) delivered **9% revenue and 8% EBITDA growth**, with **~160 bps margin expansion** on procurement and doctor cost optimization. * **Focus Unit Turnaround:** Underperforming units (~29% of revenue) achieved **~520 bps margin expansion** and **1% EBITDA growth**, now profitable with sustained operational improvements. * **Emerging Unit Progress:** Newer units (~7% of revenue) turned from loss to **₹10 Cr EBITDA profit**, with **~140 bps margin expansion**, indicating successful ramp-up. ## D. Ancillary & Segment Performance * **Labs Profitability Inflection:** Aster Labs achieved **positive EBITDA margins (YTD: 2%)**, driven by **35% external business growth** and improved operating leverage. * **Wholesale Pharma Stabilization:** Segment reached **8% EBITDA margin (9M)** and **first positive ROCE**, after outsourcing loss-making operations. * **Strategic Prioritization:** Management prioritizes **high-margin quality growth** over scale in wholesale pharma, with no plans for aggressive expansion. ## E. Balance Sheet & Liquidity * **Robust Financial Position:** Strong liquidity with **cash of ₹1,255 Cr** and **gross debt of ₹631 Cr**, providing flexibility for ongoing operations and selective growth. * **Kerala Cluster Resilience:** Entire cluster, including new Kasargod unit, performing well with flagship **MIMS Calicut at 5% operating margins**. --- # 2. Patient Volumes & ARPP ## A. Key Figures * Inpatient Volumes: 11% YoY Kerala cluster (+8% ex-Kasargod) · 4% YoY A&T cluster · 12% YoY decline in medical specialties * **ARPOB:** **~₹47,000** (+2% YoY) · **₹77,000** in Bangalore · **75–80k** sustainable range * **MVT Growth:** **41% YoY** overall · **64% YoY** MVT revenues in Kerala ## B. Inpatient Volumes & Cluster Performance * **Kerala Remains Core Growth Engine:** Strong volume and revenue momentum anchored by robust demand, improved case mix, and leadership in Oncology; MVT surge from Maldives and Oman underscores regional dominance. * **A&T and Karnataka Show Pricing Power:** Solid revenue growth driven by double-digit ARPP IP gains despite modest volume increases, reflecting disciplined pricing and favorable shift toward complex procedures. * **Bangladesh and South India Recovery:** Bangladesh demonstrates resilience with strong top-line growth; Tirupati outperforms budget, while Vijayawada, Guntur, and Ongole rebound post-clinician attrition. ## C. ARPP & Payor Mix Dynamics * **Favorable Payor Shift Enhances Quality of Earnings:** Company-wide insured mix now exceeds **80%**, reducing volatility and supporting sustainable ARPP expansion, particularly in central Kerala. * **ARPP IP Over ARPOB as Key Metric:** In markets like northern Kerala with high cash pay (75–80%), ARPP IP is a more reliable performance indicator than ARPOB due to case mix fluctuations. * **ALOS Impacts Revenue Efficiency:** Lower ALOS boosts ARPOB by improving revenue-to-occupancy efficiency; in Kerala, longer stays contribute 7% to ARPOB growth, but ARPP improvements remain primary driver. ## D. Medical Value Travel (MVT) Momentum * **MVT Surge Signals Brand Strength:** 64% revenue growth in Kerala driven by revived international patient inflows, particularly from Maldives and Oman, with management signaling sustainable trajectory. --- # 3. Capacity & Bed Expansion ## A. Key Figures * **Total Bed Capacity:** **10,620+ beds** across 28 cities (+560+ beds YoY) · **5,451 beds** in Aster network (20 hospitals) * **Expansion Pipeline:** **>4,000 additional beds** planned (to reach **14,710+ total**) · **~1,700 beds** to be added in next 3–4 years via **~INR 2,000 Cr** investment * **Near-Term Additions:** **~900 beds** expected next year (**700 greenfield**, **200 brownfield**) * **Ownership & Integration:** Stake in Aster Aadhar increased to **99%** (+12%) ## B. Expansion Strategy & Execution * **Balanced Growth Model:** Expansion driven by **greenfield projects, brownfield ramp-ups, and strategic M&A**, with capital efficiency prioritized through phased, demand-led deployment. * **Tier-2/3 Focus:** Over **75% of upcoming bed additions** targeted in non-Metro markets, enhancing healthcare access and capturing underserved demand. * **Merger Synergies:** Greenfield projects represent **over 50% of combined entity’s new capacity**, with **10–15% EBITDA synergies** expected within 2–3 years. ## C. Greenfield Development * **Trivandrum & Hyderabad First:** Only two greenfield projects expected next year—**Trivandrum (early H2)** and **Hyderabad (H2)**—both leveraging **existing QCIL assets** for faster integration and ramp-up. * **Sarjapur Delayed:** Sarjapur Road hospital commissioning pushed to **beginning of FY28** due to approval delays, though construction is now underway. * **Future-Ready Design:** Minor timeline adjustments due to **bunker addition**, but project remains on track with parallel talent and operational planning. ## D. Brownfield Ramp-up * **Kasargod Success Story:** New facility achieved **rapid ramp-up**—**50–55 beds operational**, **400+ daily outpatients**, **120+ doctors onboarded**—with **monthly losses reduced to INR 2–5 Cr** and path to **cost neutrality in next quarter**. * **Phased Capacity Release:** Hospitals typically launch with **75–80 beds**, expanding by **30 beds** upon reaching **60–65% occupancy**, ensuring disciplined scaling. * **QCIL’s Brownfield Focus:** **~89–90% of QCIL’s expansion** is brownfield, with **155–190 beds in FY27**, **~780 beds in FY28**, and **750+ beyond FY29**, all via existing facilities. ## E. Occupancy & Clinical Trends * **Kerala Cluster Strength:** Flagship **Aster Medcity** delivered **20%+ quarterly growth**, generating **>₹90 Cr/month** for 5–6 months, underpinned by strong clinical leadership and expansion. * **High-Return Expansions:** Bed additions in **Bhubaneswar and Raipur**—both capacity-constrained, profitable units—are **not margin-dilutive** due to **higher acuity services** (e.g., oncology, linear accelerators). * **Women’s Care Priority:** **Over 60% of total capacity** is dedicated to women’s and children’s health, aligning with strategic focus and market demand. --- # 4. Specialty & Service Mix ## A. Key Figures * **CONGO Mix:** Improved by **150 bps** to **54.4%** in Q3 FY26 * CONGO-T Share: Up 60 bps YoY to 57.6% * **Oncology Revenue Growth:** **+27% YoY** in Q3 * **Cardiology Revenue Growth:** **+22% YoY** in Q3 * **Robotic Procedures:** **+100% YoY**, averaging **300/month** * **Non-Census Bed Share:** **24%** (Aster, ex-QCIL) vs. **15–16%** (QCIL) ## B. CONGO-T & Strategic Mix Shift * **Accelerated CONGO-T Expansion:** Strategic shift toward high-acuity care is gaining momentum, supported by strong YoY mix improvement and over **100 clinician hires** in recent quarters. * **Tier-2/3 Capability Buildout:** Advanced services like transplants and oncology are being successfully scaled in non-metro markets, underpinning **sustained CONGO-T mix uplift** and reducing patient outflow. * **Post-Merger Mix Target:** Combined entity is targeting a **60–65% CONGO-T mix**, with QCIL expected to reach **mid-60s** and Aster already in the **mid-50s**, driven by dedicated cancer center rollouts and LINAC investments. ## C. Oncology as Core Growth Engine * **Oncology Momentum Intensifies:** Specialty now represents **11% of revenue** (up from 8–9% two years ago) and is on track to reach **high teens percentage** in 4–5 years, with **strong EBITDA contribution per bed**. * **Technology-Led Differentiation:** Partnership with **Elekta** to deploy **five LINACs** and a centralized oncology planning system enhances clinical quality and scalability across the network. * **Women & Children’s Oncology Expansion:** New multi-specialty projects include dedicated **oncology for women and pediatric sub-specialties**, building on prior experience and expanding service depth. ## D. Robotics & Advanced Care Penetration * **Robotic Surgery at Scale:** Strategic partnership with **Intuitive Surgical** to add **five robotic systems**, positioning the group as the **first in India to scale robotics in Tier-2 markets** across general surgery, gynecology, and gastroenterology. * **High Utilization & Revenue Contribution:** Robotic program already performing **80–90 surgeries/month**, with **60% in soft tissue**, demonstrating strong clinical adoption and monetization. ## E. Non-Census Beds & Lab Monetization * **Structural Clarity on Bed Classification:** Higher non-census bed share (24% vs. peers) reflects consistent inclusion of **emergency, daycare, pre-op/post-op, and dialysis beds**, not methodology changes. * **Non-Captive Lab Growth Push:** Aster Labs aims to increase **non-captive revenue from 30–31% to over 50%**, supported by a **dedicated retail-focused app** to drive external volume and margin expansion. --- # 5. Cost & Clinical Efficiency ## A. Key Figures * ALOS: 3.9 days (–3.4% YoY) · sub-4 days at QCIL * Material Cost Ratio: Reduced from 25.5% to 20.9% over three years * **Monthly Loss Avoided:** **₹1–2 Cr** from wholesale pharma exit * **Robotic Procedures:** **80–90 monthly** at MedCity * **Procurement Scale:** **₹2,000 Cr** combined post-merger (Aster + QCIL) ## B. Material Costs * **Wholesale Pharmacy Turnaround:** Strategic exit eliminated a ₹1–2 Cr monthly loss; business now profitable with **stable 3–5% net margins**, though growth potential remains limited. * **Case Mix Pressure:** Rising material costs driven by higher oncology, neuro (doubled DBS cases), and robotic procedure volumes, with **oncology accounting for 60% of the cost impact**. * **Oncology Margin Challenge:** Medical oncology dominates case mix (60%), where **70% of patient yield goes to materials**, and **immunotherapy/targeted therapies carry zero margins**. * **Efficiency Gains:** Despite adverse mix, material cost ratio improved significantly over three years due to centralized procurement and operational discipline. ## C. Procurement Synergies * **Synergy Execution:** Early EBITDA growth reflects success in **procurement centralization**, **in-sourcing**, and **clinical talent strengthening**, with Nagercoil unit contributing profitability since October 2024. * **Internal QCIL Synergies Realized:** Significant efficiency gains already achieved within QCIL network (KIMS, CARE, Evercare), improving margins ahead of Aster integration. * **Top Synergy Priority:** **Consolidated ₹2,000 Cr procurement** is critical for 10–15% EBITDA upside, with **joint negotiations and formulary optimization** expected to deliver highest margin impact within 6–12 months post-merger. ## D. ALOS Reduction * **Industry-Leading Efficiency:** ALOS reduced to **9 days** (–4% YoY) across the platform, driven by **short-stay procedures**, **minimally invasive surgeries**, and **optimized clinical protocols**. * **Oncology & Robotics Impact:** **50–60% of oncology revenue from chemotherapy** supports high daycare utilization; **robotic/keyhole surgeries** are key drivers of low ALOS, especially at MedCity. * **Quality-Driven Stays:** Strong infection control and centralized monitoring reduce complications and further shorten stays. * **Post-Merger ALOS Upside:** QCIL’s current higher ALOS (vs. Aster) expected to decline with adoption of **oncology-focused and robotic care models**, bringing in high-yield, low-length-of-stay patients. ## E. Talent Costs * **Hiring Ramp-Up:** New clinical hires underway, with **margin and volume benefits expected over 3–4 quarters** as integration deepens and throughput increases. --- # 6. Risks & Clinical Retention ## A. Key Figures * **Clinicians Onboarded:** **100+** YTD FY26 * **MRR from New Clinicians:** **₹24 Cr** (Quarterly) * **Revenue in Kerala (excl. Kasargod):** **₹619 Cr**, flat YoY * **Clinician Base in Kasargod:** **120** ## B. Clinician Attrition * **Proactive Talent Management:** Strong onboarding momentum with **100+ clinicians** hired YTD, driving **₹24 Cr in quarterly MRR**, signaling effective scaling of clinical capacity. * **Retention as Competitive Advantage:** High retention and a growing trend of **former clinicians rejoining** reflect strong organizational culture and positioning as an employer of choice. * **Targeted Expansion in High-Competition Markets:** Strategic focus on hiring **top-tier specialists** in Bengaluru and specialized women’s care in Hyderabad to counter intensifying competition and strengthen key clusters. * **K&M Cluster Under Pressure:** Performance softness in Karnataka due to seasonality, scheme changes, and clinician movements; replacement efforts ongoing but **normalized operations timeline unclear**. ## C. Market Competition * **Elite Talent Targeting:** Aggressive pursuit of **top 1–3 clinicians in core specialties** (e.g., CONGO-T mix) in Bengaluru to consolidate market leadership amid rising rivalry. ## D. Integration Delays * **Margin Pressure from Talent Investment:** Elevated costs in Kerala weighed on margins despite flat revenue, reflecting **strategic reinvestment in clinical teams** rather than operational underperformance. * **Limited Near-Term Impact from New Projects:** Expansion in Tier-2/3 cities (e.g., Kasargod) expected to contribute only in **H2**, with minimal full-year financial impact. --- # 7. Guidance & Outlook ## A. Key Figures * **Capex (9M FY26):** **₹406 Cr** (nearly 50% for expansion) * EBITDA Loss (New Units): ₹2.5–4 Cr/month average in first 6 months of operation * **ARPP IP Growth (Kerala):** **6–8%** sustainable mid-term outlook (next 3–4 years) ## B. EBITDA Targets * **Margin Roadmap:** Targeting **24–25% EBITDA margins** in 2–3 years despite near-term dilution from Greenfield rollouts. * **Greenfield Launch Timing:** Sarjapur unit expected to launch in **H2 FY28**, with early-stage losses anticipated across new facilities. ## C. Capex Plans * **Expansion-Focused Spending:** Nearly half of year-to-date capital expenditure directed toward new capacity projects. ## D. Merger Timeline * **Merger on Track for Q1 FY27:** Regulatory and exchange approvals secured; shareholder vote scheduled between **Feb 27–Mar 13, 2026**, with NCLT sanction expected to follow. * **Post-Merger Synergies:** Procurement and operational efficiencies, including pharmacy integration, expected only after closing; no current financial impact. ## E. Growth Projections * **Kerala Drives Core Growth:** Region remains profitability anchor, with stable ARPP expansion supported by favorable payor trends. * **New Market Potential:** Trivandrum and Hyderabad greenfield sites target strong initial utilization, leveraging underpenetrated or high-demand geographies. * **Retail Pharmacy Path to Profitability:** Segment on track to reach break-even within **1–2 years** amid solid performance. * **Controlled Growth Strategy:** Company aims to moderate overall growth pace below **21%** through stabilized specialty expansion.